Inicio › Mieloma múltiple › Georgia › Atlanta
Ensayos clínicos de Mieloma múltiple en Atlanta, GA
42 estudios para Mieloma múltiple buscan participantes en centros de Atlanta y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
ReclutandoFase 3
- Emory University Hospital Midtown, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
ReclutandoFase 1
- Winship Cancer Institute of Emory University, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
ReclutandoFase 3
- Emory University - Winship Cancer Institute, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutandoFase 4
- Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 2
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ReclutandoFase 1
- Emory Winchip Cancer Center, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 2
- Winship Cancer Institute, Emory University, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutandoFase 1
- Winship Cancer Institute, Emory University, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
ReclutandoFase 1/2
- Research Site, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutandoFase 3
- Winship Cancer Institute, Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
ReclutandoEstudio observacional
- Emory University, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1/2
- Emory University Hospital, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
ReclutandoFase 1/2
- Emory University Winship Cancer Center, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ReclutandoFase 1
- The Winship Cancer Institute of Emory University, Atlanta
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
ReclutandoFase 3
- Research Site, Atlanta
- Research Site, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ReclutandoFase 1/2
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ReclutandoFase 2/3
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1/2
- Research Site, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
ReclutandoFase 2
- Caitlin Guzowski, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutandoFase 1/2
- Research Site, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 2
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
ReclutandoFase 2
- Emory University (Data Collection Only), Atlanta
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutandoFase 3
- Research Site, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- Emory University, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
ReclutandoFase 1
- Winship Cancer Institute Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
ReclutandoFase 1
- Research Site, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1/2
- Emory University Hospital, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
ReclutandoFase 1/2
- Winship Cancer Institute of Emory University, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
ReclutandoFase 2
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
ReclutandoFase 1
- Emory University Hospital, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ReclutandoFase 3
- Research Site, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
ReclutandoFase 4
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
ReclutandoFase 1
- Northside Hospital, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ReclutandoFase 1/2
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
ReclutandoFase 1
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Reclutando
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
ReclutandoFase 3
- GSK Investigational Site, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ReclutandoFase 1
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
ReclutandoFase 1/2
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
ReclutandoFase 1
- Northside Hospital, Atlanta
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY59 estudios
- Boston, MA45 estudios
- Houston, TX39 estudios
- Durham, NC36 estudios
- Nashville, TN31 estudios
- Denver, CO26 estudios
- St. Louis, MO26 estudios
- Rochester, MN25 estudios
- Columbus, OH25 estudios
- Chicago, IL24 estudios
- Milwaukee, WI23 estudios
- Baldwin Park, CA23 estudios
Otros estudios en Atlanta
- Cáncer (todos los tipos)49 estudios
- Cáncer de pulmón de células no pequeñas48 estudios
- Cáncer de seno42 estudios
- Cáncer de próstata36 estudios
- Leucemia mielógena aguda30 estudios
- Cáncer metastásico29 estudios
- Cáncer de ovario29 estudios
- Cáncer del colon y del recto29 estudios
- Cáncer de pulmón28 estudios
- Obesidad26 estudios
- Trastorno depresivo mayor24 estudios
- Fallo cardíaco23 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.